PEG & ADCs
- Radionuclide Drug Conjugates (RDCs): Current Status
- Global Sales of ADCs in 2023 – UP to 10 Billion
- FDA Approved Antibody-Drug Conjugates (ADCs) By 2024
- Antibody–Drug Conjugates Targeting MUC1
- Three ADCs Expected To Be Approved In 2024-2025
- What Are ADC Payloads?
- ADCs, SMDCs and DACs for Cancer Treatment
- ADC in Combination with PD-1: Approvals and Clinical Trials
- Summary of Approved HER2 ADCs on The Market & in Clinical Trials
- Topoisomerase I inhibitors Based ADCs: SN-38 & DXd